Qiagen and Institut Curie have announced a collaboration to develop tools for high-throughput RNAi screening as part of the Institut Curie BioPhenics project.
This project, led by Drs Jacques Camonis and Franck Perez, aims to use RNAi technology in conjunction with advanced systematic phenotypic analysis to accelerate cancer drug discovery.
“As one of the largest cancer research centers in Europe, part of the ongoing research at Institut Curie is dedicated to the understanding of how cells become cancerous,” said Jacques Camonis, head of the BioPhenics project in the Translational Department at Institut Curie.
“The goal of the 'BioPhenics' project is to apply cell biology and microscopic imaging to cancer research for a deeper understanding, improved target validation and, ultimately, more efficient cancer drug discovery.”
“Qiagen is pleased to be able to contribute to this ambitious and exciting research,” said Jie Kang, V.P. of R & D at Qiagen.
“The combination of Qiagen advanced siRNA design and extremely efficient HiPerFect delivery reagent should contribute greatly to the overall goals of the project.”